Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SBK Biomedical

Request full access

Pioneering anti-cancer drugs in China with a focus on cardiovascular and respiratory diseases

ChinaFounded 2015Biotech & Life Sciences

About SBK Biomedical

Shebacon is a pharmaceutical company dedicated to the research and development of new drugs, particularly in the field of anti-cancer medications. The company operates within the Chinese market, aiming to address the historical challenges faced by Chinese anti-cancer drugs in gaining acceptance. By focusing on diseases affecting the cardiovascular and respiratory systems, Shebacon has advanced several products to the clinical trial phase. The business model revolves around sustaining corporate innovation through a four-way drive, positioning itself as a leader in global drug differentiation. Revenue is generated through the development and eventual commercialization of these specialized medications. Shebacon's recognition as a Growing Enterprise for Urban Small and Medium Sized Enterprises in both 2022 and 2023 underscores its commitment to growth and innovation in the pharmaceutical sector.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
China
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Cardiology and cardiovascular, Respiratory, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Aug 2025 $14M $55M Chengda Pharmaceutical ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

SBK Biomedical website traffic

Latest recorded traffic for SBK Biomedical is 140 monthly website visits.

Latest monthly visits140
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SBK Biomedical in its local ecosystem

Live from Dealroom

The SBK Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Chengda Pharmaceutical
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SBK Biomedical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SBK Biomedical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.